Lyon- France - Created in March 2021, APM, which has 22 members, is the result of the union of public and private actors committed to promoting the emerging science of the microbiota. As the spokesperson and convener of major players in the development, production and commercialization of therapeutic innovations related to the microbiota in France, APM announced the composition of its Board of Directors and its Office. Composed of 11 members, the Board of Directors will have the task of defining, with the help of the other members of the association, the strategy of the MPA and the associated action plans. Its objective: to make France, a pioneer in the microbiota industry, a European leader and to meet the current and future challenges of this industry, which was recognized in 2021 as a priority under the 'Health Innovation Plan 2030'.
Composition of the new Board of Directors of Alliance Promotion Microbiota (listed in alphabetical order):
The College of Developers brings together structures
developing a product with a regulatory status (drug, medical device, in vitro diagnostic device, etc.). * Herve Affagard, CEO and co-founder of MaaT Pharma
Sylvie Binda, Vice President R&D of Lallemand Health Solutions
Nicolas Coudurier, CEO of Biocodex
Sophie Durand, CEO of Stellate Therapeutics
Etienne Formstecher, CEO and co-founder of GMT Science
Pierre-Yves Mousset, CEO of Novobiome
The College of Associates brings together structures such as management companies financing microbiota companies; preclinical and clinical R&D companies ('Contract Research Organization' / CDMO).
Isabelle de Cremoux, Chairman of the Executive Board of Seventure Partners
Benoit Fouchaq, Managing Director of Biofortis Europe
Adrien Nivoliez, CEO of Biose Industrie
The College of Clusters and Institutions brings together structures such as incubators, clusters, competitiveness clusters; research institutes; valuation entities; SATT; hospitals, clinics; care facilities; technopoles; metropolises; regional bodies.
Florence Agostino-Etchetto, CEO of Lyonbiopole
Vincent Thomas, Director of the Microbiota Program at Bioaster
Following the General Meeting held on January 13, 2022, the 11 members of the Board of Directors elected Herve Affagard, CEO and co-founder of MaaT Pharma, as President of Alliance Promotion Microbiote and a new office was formed with the appointment of Sylvie Binda, Vice President R&D of Lallemand Health Solutions, as Vice President, Vincent Thomas, Director of the Microbiota Program at Bioaster, as Secretary and Adrien Nivoliez, General Manager of Biose Industries, as Treasurer.
'Thanks to its scientific, industrial and funding ecosystem, France has historically been a pioneer in the microbiota industry. In recent years, however, it has experienced a loss of momentum in the face of the growing number of international initiatives in this field. APM's ambition is to federate private and public actors around a well-known, recognized and impactful entity in order to collectively promote national expertise and allow France to assert and develop its leadership in this promising industry. A real point of convergence for its members, APM is developing with a view to diversity, exchange of good practices and mutual assistance with the objective of defining strategies and tools to accelerate the development of innovative products from the microbiota. APM wishes to intensify its position as spokesperson for the leading players in the microbiota ecosystem in France in order to highlight the sector and carry a strong common ambition.' says Herve Affagard on behalf of APM.
Since its creation less than a year ago, APM has already worked significantly for the French sector and its stakeholders. Indeed, it carried out the first sectoral study on the microbiota in France and its positioning at the international level (available on request via e-mail at contact@apmicrobiote.com). APM has also helped to highlight the sector and the most advanced French innovations at events such as BIG-BPI France, etc. APM also plays a role as a spokesperson for the ecosystem during discussions with public authorities, notably in the context of the Strategic Committee of Health Industries (CSIS) and the Bioethics Bill.
Young and promising, the French microbiota industry has many assets and represents a concrete opportunity for France to become a European leader. Today, France is in the top 3 of the most advanced countries in the microbiota (behind the United States and South Korea) and the first (and only) European nation in the top 5 worldwide. In order to contribute to the promotion and development of the sector, Alliance Promotion Microbiota has defined 6 strategic axes:
1. encourage fundamental and applied research and fully integrate it into the sector
2. structuring the French ecosystem to attract investment3. support the development of French production capacities 4. secure the upstream value chain, particularly from a regulatory perspective 5. facilitate the arrival and access of new therapies 6. position France as a driving force and European leader
About Alliance Promotion Microbiota
Alliance Promotion Microbiota aims to promote the French ecosystem involved in the emerging science of the microbiota. Its objective is to build an ecosystem of excellence positioning France as a European leader in the development, production and commercialization of scientific and therapeutic innovations related to the microbiota. The Members of Alliance Promotion Microbiota are Bioaster, Biocodex, Biofortis, Biose Industrie, Cynbiose, Da Volterra, Eligo Bioscience, EverImmune, GMT Science, INRAE, INSERM, Lallemand Health Solutions, Lyonbiopole, MaaT Pharma, Medicen, Microbiome Fundation, Nexbiome, Novobiome, Seventure Partners, Stellate Therapeutics, TargEDys, Ysopia Bioscience.
Contact:
MaaT Pharma
70 avenue Tony Garnier
69007 Lyon
Email: invest@maat-pharma.com
Phone: 04 28 29 14 00
MAAT PHARMA 
